Stockscreener 앱 받기
6.81
0.74%
0.05
시간 외 거래:
6.88
0.07
+1.03%
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
Notice to Long-Term Shareholders of ASP Isotopes Inc. - GlobeNewswire
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics (NASDAQ:UNCY) Shares Down 0.4%Here's Why - MarketBeat
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Integer Holdings Corp. (NYSE: ITGR): Molina Healthcare, Inc. (NYSE: MOH); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Boston - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Unicycive Therapeutics (UNCY) price target decreased by 12.88% to 47.43 - MSN
Aug Setups: Is Unicycive Therapeutics Inc on track to beat earningsTrade Volume Report & Fast Gain Stock Tips - baoquankhu1.vn
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm - TMX Newsfile
Unicycive Therapeutics : March 2026 Corporate Presentation - marketscreener.com
Important Notice to Long-Term Shareholders of Corcept - GlobeNewswire
UNCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
UNCY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Unicycive's OLC Address Hyperphosphatemia's Unmet Need With Its 3P Advantage? - RTTNews
Unicycive’s Kidney Drug Pipeline Puts A Small Stock On The Clock - Finimize
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Unicycive Therapeutics Inc. benefit from current market trendsJuly 2025 Snapshot & Verified Entry Point Signals - mfd.ru
Why is Unicycive Therapeutics Inc. stock going downJuly 2025 Spike Watch & Comprehensive Market Scan Insights - mfd.ru
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-02-19 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4%Should You Buy? - MarketBeat
2026-02-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - marketscreener.com
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Will Unicycive Therapeutics Inc. stock go up in YEAR2025 Trade Ideas & Safe Entry Zone Tips - mfd.ru
UNCY Should I Buy - Intellectia AI
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | NDAQ:UNCY | Press Release - Stockhouse
Octagon discloses 1M Unicycive (UNCY) shares, holding under 5% - Stock Titan
Unicycive Therapeutics: Speculative Biotech Stock Whipsaws Traders As Wall Street Stays Cautious - AD HOC NEWS
Investor Mood: Is Open Lending Corporation stock a top performer YTDWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - The Manila Times
Biotech CEO Shalabh Gupta set for Guggenheim fireside chat Feb. 11 - Stock Titan
Unicycive Therapeutics Doubles Stock Sale Agreement - MSN
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
Take two: Company tries again to win FDA approval for drug for dialysis patients - The Business Journals
Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate (OLC) new drug application (NDA) resubmission - marketscreener.com
UPDATEUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance Of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - TradingView
Unicycive granted FDA review for resubmitted marketing application for kidney disease drug - Seeking Alpha
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance of - GlobeNewswire
FY2030 Earnings Forecast for UNCY Issued By HC Wainwright - Defense World
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
2026-01-27 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Analysts Set Expectations for UNCY FY2030 Earnings - MarketBeat
Trading Action: Will Unicycive Therapeutics Inc benefit from current market trends2025 Growth vs Value & Fast Entry and Exit Trade Plans - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):